HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)’s share price traded up 6.2% on Thursday . The company traded as high as $2.35 and last traded at $1.83. 534,282 shares changed hands during mid-day trading, an increase of 34% from the average session volume of 397,629 shares. The stock had previously closed at $1.95.

A number of equities analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of HTG Molecular Diagnostics in a report on Tuesday, September 12th. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.75.

The company’s 50 day moving average is $1.87 and its 200-day moving average is $1.87. The firm’s market cap is $21.06 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.80 million. On average, analysts anticipate that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current year.

In other HTG Molecular Diagnostics news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $1.81, for a total transaction of $2,081,161.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 1,659,998 shares of company stock valued at $3,073,696. Corporate insiders own 7.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. UBS Group AG bought a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $137,000. Two Sigma Securities LLC bought a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $150,000. Granahan Investment Management Inc. MA bought a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $228,000. Finally, Vanguard Group Inc. grew its stake in shares of HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after purchasing an additional 37,841 shares during the period. Institutional investors and hedge funds own 21.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) Trading -6.2% Higher” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/23/htg-molecular-diagnostics-inc-htgm-trading-6-2-higher.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.